Inhibrx Biosciences, Inc. (INBX)
Nasdaq: INBX · Biological Products, (No Diagnostic Substances) · La Jolla, CA · filing with the SEC since 2024
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts in thousands. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Mar 19, 2026 | Mar 17, 2025 | · |
| Revenue | 1,300 | 200 | 1,800 |
| Research and development | 113,028 | 203,743 | 191,640 |
| General and administrative | 23,297 | 127,905 | 29,381 |
| Total operating expenses | 136,325 | 331,648 | 221,021 |
| Operating income | -135,025 | -331,448 | -219,221 |
| Interest expense | 12,196 | 13,491 | 31,840 |
| Share of profit of equity-method investments | · | 0 | -1,634 |
| Other income (expense), net | -381 | 75 | -580 |
| Total non-operating income (expense) | -5,028 | 2,019,022 | -20,503 |
| Income before income taxes | -140,053 | 1,687,574 | -239,724 |
| Income tax expense | 2 | 2 | 3 |
| Net income | -140,055 | 1,687,572 | -241,361 |
| Earnings per share, basic | -9.04 | 114.01 | -20.48 |
| Earnings per share, diluted | -9.04 | 112.62 | -20.48 |
| Weighted average shares, basic | 15,487 | 14,802 | 11,783 |
| Weighted average shares, diluted | 15,487 | 14,984 | 11,783 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingShare of profit of equity-method investments its share of companies it partly owns
us-gaap:IncomeLossFromEquityMethodInvestmentsOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding